GregoryAramSahagianMD

Clinical Trials

• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) Start of enrollment: 2016 Feb 11

  Completed

  Phase 3

• A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia Start of enrollment: 2016 Jul 01

  Terminated

  Phase 3

• Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine Start of enrollment: 2016 Jul 22

  Completed

  Phase 3

• A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. Start of enrollment: 2019 Mar 01

  Completed

  Phase 3

• A Study of RVT-1401 in Myasthenia Gravis (MG) Patients Start of enrollment: 2019 May 21

  Completed

  Phase 2

• Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) Start of enrollment: 2019 Apr 22

  Completed

  Phase 2

• Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations Start of enrollment: 2019 Sep 30

  Active, not recruiting

  Phase 3

• A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Start of enrollment: 2020 Sep 18

  Active, not recruiting

  Phase 2

• A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Start of enrollment: 2020 Apr 15

  Completed

  Phase 2

• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Start of enrollment: 2020 Jun 19

  Active, not recruiting

  Phase 3

• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) Start of enrollment: 2020 Nov 26

  Active, not recruiting

  Phase 3

• Synuclein-One Study Start of enrollment: 2021 Jan 04

  Completed

• Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis Start of enrollment: 2021 Feb 05

  Completed

  Phase 3

• Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention Start of enrollment: 2021 Apr 13

  Completed

  Not Applicable

• Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) Start of enrollment: 2019 Dec 04

  Recruiting

  Phase 2

• An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis Start of enrollment: 2021 Dec 16

  Active, not recruiting

  Phase 3

• Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis Start of enrollment: 2022 Jun 27

  Recruiting

  Phase 3

• A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants With Early Alzheimer's Disease (ALTITUDE-AD) Start of enrollment: 2024 Feb 29

  Recruiting

  Phase 2, Phase 3

• A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine Start of enrollment: 2019 Nov 07

  Completed

  Phase 3

• Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease Start of enrollment: 2021 Nov 18

  Active, not recruiting

  Phase 3

• Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
• Join now to see all